CONTACT-02: Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Sponsor

Exelixis (Industry)

Overall Status

Recruiting

CT.gov ID

NCT04446117

Collaborator

Roche-Genentech (Industry), Takeda (Industry)

580

Enrollment

233

Locations

Arms

Anticipated Duration (Months)

2.5

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.

Condition or Disease	Intervention/Treatment	Phase
Metastatic Prostate Cancer Prostate Adenocarcinoma	Drug: Cabozantinib Drug: Atezolizumab Drug: Abiraterone Acetate Drug: Enzalutamide Drug: Prednisone	Phase 3

Detailed Description

The primary objective of this study is to evaluate the efficacy of cabozantinib (XL184) in combination with atezolizumab versus a second NHT (abiraterone or enzalutamide) in subjects with mCRPC who have previously been treated with one, and only one, NHT (e.g. abiraterone, apalutamide, darolutamide, or enzalutamide) to treat metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic CRPC (M0 CRPC), or mCRPC, and who have measurable extrapelvic disease. The multiple primary efficacy endpoints comparing the experimental arm and control arm are Duration of Progression Free Survival (PFS) per RECIST 1.1 by Blinded Independent Radiology Committee (BIRC) and Duration of Overall Survival (OS). The secondary efficacy endpoint is Objective Response Rate (ORR) per RECIST 1.1 per BIRC.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

580 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Approximately 580 eligible subjects will be randomized in a 1:1 fashion to the experimental arm receiving cabozantinib and atezolizumab in combination (290) or to the control arm receiving a second NHT (290).Approximately 580 eligible subjects will be randomized in a 1:1 fashion to the experimental arm receiving cabozantinib and atezolizumab in combination (290) or to the control arm receiving a second NHT (290).

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer

Actual Study Start Date :

Jun 30, 2020

Anticipated Primary Completion Date :

Mar 30, 2022

Anticipated Study Completion Date :

Jul 30, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Experimental Arm Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w	Drug: Cabozantinib Supplied as 20-mg tablets; administered orally daily at 40mg Other Names: XL184 Cabometyx® Drug: Atezolizumab Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w) Other Names: Tecentriq®
Active Comparator: Control Arm Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization	Drug: Abiraterone Acetate Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid Other Names: Abiraterone Zytiga Drug: Enzalutamide Supplied as 40 mg capsules; administered orally daily at 160mg Other Names: Xtandi Drug: Prednisone Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily

Arm

Intervention/Treatment

Experimental: Experimental Arm

Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w

Drug: Cabozantinib

Supplied as 20-mg tablets; administered orally daily at 40mg

Other Names:

XL184

Cabometyx®

Drug: Atezolizumab

Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)

Other Names:

Tecentriq®

Active Comparator: Control Arm

Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization

Drug: Abiraterone Acetate

Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid

Other Names:

Abiraterone

Zytiga

Drug: Enzalutamide

Supplied as 40 mg capsules; administered orally daily at 160mg

Other Names:

Xtandi

Drug: Prednisone

Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily

Outcome Measures

Primary Outcome Measures

Duration of Progression Free Survival per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1) [Approximately 21 months after the first subject is randomized.]
Defined as time from randomization to the earlier of progressive disease (PD) per RECIST 1.1 as determined by the Blinded Independent Radiology Committee (BIRC) or death from any cause
Duration of Overall Survival (OS) [Approximately 37 months after the first subject is randomized]
Defined as time from randomization to date of death from any cause

Secondary Outcome Measures

Objective response rate (ORR) [Approximately 37 months after the first subject is randomized]
ORR per RECIST 1.1 by BIRC

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

Men with histologically or cytologically confirmed adenocarcinoma of the prostate
Prior treatment with one, and only one, NHT (eg, abiraterone, apalutamide, darolutamide, or enzalutamide) for castration-sensitive locally advanced (T3 or T4) or mCSPC, M0 CRPC, or mCRPC
Surgical or medical castration, with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening
Measurable (extrapelvic soft tissue) metastatic disease per Investigator assessment defined by at least one of the following: measurable visceral disease (eg, adrenal, kidney, liver, lung, pancreas, spleen) per RECIST 1.1; OR measurable extrapelvic adenopathy (ie, adenopathy above the aortic bifurcation)
Progressive disease at study entry as defined by specific criteria for prostate specific antigen (PSA) progression OR soft tissue disease progression in the opinion of the Investigator (Note: subjects with bone disease progression alone are not eligible)
Age ≥ 18 years old or meeting country definition of adult, whichever is older, on the day of consent
ECOG performance status of 0 or 1
Recovery to baseline or ≤ Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) v5 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy in the opinion of the Investigator
Adequate organ and marrow function based upon specific laboratory assessments obtained within 21 days prior to randomization
Understanding and ability to comply with protocol requirements

Exclusion Criteria:

Any prior nonhormonal therapy initiated for the treatment of mCRPC
Receipt of abiraterone within 1 week; cyproterone within 10 days; or flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen-receptor inhibitors within 2 weeks before randomization
Radiation therapy within 4 weeks (2 weeks for bone metastases) prior to randomization (subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible)
Known brain metastases or cranial epidural disease unless adequately treated and clinically stable at least 4 weeks prior to randomization
Symptomatic or impending spinal cord compression or cauda equina syndrome
Concomitant anticoagulation with oral anticoagulants (some specific exceptions apply)
Administration of a live, attenuated vaccine within 30 days prior to randomization
Systematic treatment with, or any condition requiring, either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to randomization
Uncontrolled, significant intercurrent or recent illness
Major surgery within 4 weeks prior to randomization
Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per ECG within 21 days before randomization
Inability or unwillingness to swallow pills or receive IV administration
Previously identified allergy or hypersensitivity to components of the study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies
Any other active malignancy at time of randomization or diagnosis of another malignancy within 2 years prior to randomization that requires active treatment (some exceptions apply such as locally curable cancers that have apparently been cured).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Exelixis Clinical Site #4	Tucson	Arizona	United States	85741
2	Exelixis Clinical Site #42	Duarte	California	United States	91010
3	Exelixis Clinical Site #2	Fullerton	California	United States	92835
4	Exelixis Clinical Site #225	La Jolla	California	United States	92093-0698
5	Exelixis Clinical Site #114	San Diego	California	United States	92161
6	Exelixis Clinical Site #125	Santa Monica	California	United States	90404
7	Exelixis Clinical Site #91	Aurora	Colorado	United States	80045
8	Exelixis Clinical Site #14	Denver	Colorado	United States	80211
9	Exelixis Clinical Site #108	Miami	Florida	United States	33125
10	Exelixis Clinical Site #216	Westwood	Kansas	United States	66205
11	Exelixis Clinical Site #6	Baltimore	Maryland	United States	21204
12	Exelixis Clinical Site #203	Rochester	Minnesota	United States	55905
13	Exelixis Clinical Site #19	Omaha	Nebraska	United States	68130
14	Exelixis Clinical Site #144	Las Vegas	Nevada	United States	89169
15	Exelixis Clinical Site #123	East Brunswick	New Jersey	United States	08816
16	Exelixis Clinical Site #198	Bronx	New York	United States	10461
17	Exelixis Site #159	Cleveland	Ohio	United States	44195
18	Exelixis Clinical Site #221	Oklahoma City	Oklahoma	United States	73104
19	Exelixis Clinical Site #18	Philadelphia	Pennsylvania	United States	19111
20	Exelixis Clinical Site #201	Pittsburgh	Pennsylvania	United States	15232
21	Exelixis Clinical Site #1	Nashville	Tennessee	United States	37209
22	Exelixis Clinical Site #5	Houston	Texas	United States	77027
23	Exelixis Clinical Site #177	Houston	Texas	United States	77030
24	Exelixis Clinical Site #41	Temple	Texas	United States	76504
25	Exelixis Clinical Site #67	Salt Lake City	Utah	United States	84112
26	Exelixis Clinical Site #143	Roanoke	Virginia	United States	24014
27	Exelixis Clinical Site #122	Ciudad Autonoma de Buenos Aire	Buenos Aires	Argentina	C1280AEB
28	Exelixis Clinical Site #120	Mar Del Plata	Buenos Aires	Argentina	B7600FZO
29	Exelixis Site #170	Pergamino	Buenos Aires	Argentina	B2700CPM
30	Exelixis Clinical Site #210	Córdoba	Cordoba	Argentina	X5004FHP
31	Exelixis Clinical Site #152	Viedma	Rio Negro	Argentina	R8500ACE
32	Exelixis Clinical Site #183	Rosario	Santa Fe	Argentina	S2000CVB
33	Exelixis Clinical Site #200	Buenos Aires		Argentina	C1426ANZ
34	Exelixis Clinical Site #44	Ciudad Autonoma de Buenos Aire		Argentina	C1012AAR
35	Exelixis Clinical Site #105	La Rioja		Argentina	F5300
36	Exelixis Clinical Site #124	San Juan		Argentina	5400
37	Exelixis Clinical Site #101	San Salvador De Jujuy		Argentina	Y4600EHA
38	Exelixis Clinical Site #151	Garran	Australian Capital Territory	Australia	2605
39	Exelixis Clinical Site #175	Saint Leonards	New South Wales	Australia	2065
40	Exelixis Clinical Site # 189	Sydney	New South Wales	Australia	2109
41	Exelixis Site #162	Wollongong	New South Wales	Australia	2500
42	Exelixis Clinical Site #103	Launceston	Tasmania	Australia	7250
43	Exelixis Clinical Site #79	Ballarat	Victoria	Australia	3350
44	Exelixis Clinical Site #95	Frankston	Victoria	Australia	3199
45	Exelixis Clinical Site #53	Melbourne	Victoria	Australia	3000
46	Exelixis Clinical Site #115	Adelaide		Australia	5000
47	Exelixis Clinical Site #149	Box Hill		Australia	3128
48	Exelixis Site #158	Linz	Oberösterreich	Austria	4020
49	Odensklinikum Linz GmbH Elisabethinen #156	Linz	Oberösterreich	Austria	4020
50	Exelixis Clinical Site #218	Wien		Austria	1080
51	Exelixis Clinical Site #126	Bonheiden	Antwerpen	Belgium	2820
52	Exelixis Clinical Site #39	Gent	Oost-Vlaanderen	Belgium	9000
53	Exelixis Clinical Site #141	Brussels		Belgium	1000
54	Exelixis Site #165	Roeselare		Belgium	8800
55	Exelixis Clinical Site #204	Curitiba	Parana	Brazil	80520-174
56	Exelixis Site #163	Curitiba	Paraná	Brazil	80510-130
57	Exelixis Site #157	Porto Alegre	Rio Grande Do Sul	Brazil	90610-00
58	Exelixis Clinical Site #171	Rio De Janeiro	RJ	Brazil	22793-080
59	Exelixis Clinical Site #132	Blumenau	Santa Catarina	Brazil	89010-340
60	Exelixis Clinical Site #191	Campinas	Sao Paulo	Brazil	13083-970
61	Exelixis Site #161	Sao Paulo	SP	Brazil	04538-132
62	Exelixis Clinical Site #128	Ribeirão Preto	São Paulo	Brazil	14048-900
63	Exelixis Clinical Site #106	São José Do Rio Preto	São Paulo	Brazil	15090-000
64	Exelixis Clinical Site #154	Barretos		Brazil	14784-400
65	Exelixis Clinical Site #140	Fortaleza		Brazil	60336-232
66	Exelixis Clinical Site #153	Porto Alegre		Brazil	90110-270
67	Exelixis Clinical Site #145	Ribeirão Preto		Brazil	14015-130
68	Exelixis Clinical Site #116	Santa Cruz Do Sul		Brazil	96810-110
69	Exelixis Clinical Site #69	Edmonton	Alberta	Canada	T6G 1Z2
70	Exelixis Clinical Site #112	Kelowna	British Columbia	Canada	V1Y 5L3
71	Exelixis Clinical Site #147	Moncton	New Brunswick	Canada	E1C 6Z8
72	Exelixis Clinical Site #83	Hamilton	Ontario	Canada	L8V 5C2
73	Exelixis Clinical Site #127	London	Ontario	Canada	N6A 5W9
74	Exelixis Clinical Site #7	Oakville	Ontario	Canada	L6H 3PI
75	Exelixis Clinical Site #178	Granby	Quebec	Canada	J2GIT7
76	Exelixis Site #160	Montréal	Quebec	Canada	H2X 3E4
77	Exelixis Clinical Site #139	Santiago de Chile	Región Metropolitana De Santiago	Chile	7500921
78	Exelixis Clinical Site #142	Providencia		Chile	7500713
79	Exelixis Clinical Site #148	Recoleta		Chile	8420383
80	Exelixis Clinical Site #90	Santiago		Chile	7500653
81	Exelixis Clinical Site #113	Temuco		Chile	4810469
82	Exelixis Clinical Site #119	Valparaíso		Chile	2540333
83	Exelixis Clinical Site #63	Praha 2	Praha	Czechia	120 00
84	Exelixis Clinical Site #129	Brno		Czechia	656 91
85	Exelixis Clinical Site #130	Olomouc		Czechia	779 00
86	Exelixis Clinical Site #80	Praha 2		Czechia	128 00
87	Exelixis Clinical Site #47	Praha 8		Czechia	180 81
88	Exelixis Clinical Site #31	Praha		Czechia	140 59
89	Exelixis Clinical Site #134	Brest		France	29229
90	Exelixis Clinical Site #77	Clermont-Ferrand		France	63011
91	Exelixis Clinical Site #155	Dijon cedex		France	21079
92	Exelixis Clinical Site #74	Hyères		France	83400
93	Exelixis Clinical Site #222	La Roche-sur-Yon Cedex 9		France	85925
94	Exelixis Clinical Site #146	Nîmes		France	30029
95	Exelixis Clinical Site #38	Paris		France	75015
96	Exelixis Clinical Site #66	Quimper		France	29107
97	Exelixis Clinical Site #213	Reims Cedex		France	51726
98	Exelixis Clinical Site #135	Saint-Grégoire		France	35760
99	Exelixis Clinical Site #212	Strasbourg		France	67000
100	Exelixis Clinical Site #36	Strasbourg		France	67200
101	Exelixis Clinical Site #73	Toulouse		France	31059
102	Exelixis Clinical Site #85	Toulouse		France	31076
103	Exelixis Clinical Site #230	Vandoeuvre les nancy		France	54511
104	Exelixis Clinical Site #16	Tbilisi		Georgia	0112
105	Exelixis Clinical Site #9	Tbilisi		Georgia	0141
106	Exelixis Clinical Site #10	Tbilisi		Georgia	0144
107	Exelixis Clinical Site #11	Tbilisi		Georgia	0159
108	Exelixis Clinical Site #15	Tbilisi		Georgia	0167
109	Exelixis Clinical Site #8	Tbilisi		Georgia	0186
110	Exelixis Clinical Site #176	Nürtingen	Baden-Wuerttemberg	Germany	72622
111	Exelixis Clinical Site #98	Gutersloh	Nordrhein-Westfalen	Germany	33332
112	Exelixis Clinical Site #180	Duisburg	North Rhine-Westphalia	Germany	47179
113	Exelixis Clinical Site #179	Münster	North Rhine-Westphalia	Germany	48149
114	Exelixis Clinical Site #185	Lübeck	Schleswig-Holstein	Germany	23538
115	Exelixis Clinical Site #228	Berlin		Germany	10117
116	Exelixis Clinical Site #136	Tübingen		Germany	72076
117	Exelixis Clinical Site #93	Cholargós	Attica	Greece	15562
118	Exelixis Clinical Site #202	Maroussi	Attica	Greece	15123
119	Exelixis Clinical Site #92	Maroúsi	Attica	Greece	15125
120	Exelixis Clinical Site #99	Néo Fáliro	Attica	Greece	18547
121	Exelixis Clinical Site #45	Heraklion	Crete	Greece	71110
122	Exelixis Clinical Site #64	Thessaloníki	Macedonia	Greece	54007
123	Exelixis Clinical Site #97	Larissa	Thessaly	Greece	41110
124	Exelixis Clinical Site #118	Budapest		Hungary	1062
125	Exelixis Clinical Site #207	Budapest		Hungary	1082
126	Exelixis Clinical Site #57	Budapest		Hungary	1122
127	Exelixis Clinical Site #109	Budapest		Hungary	1145
128	Exelixis site #167	Gyula		Hungary	5700
129	Exelixis Clinical Site #55	Haifa		Israel	3109601
130	Exelixis Clinical Site #27	Jerusalem		Israel	9112001
131	Exelixis Clinical Site #150	Petah tikva		Israel	4941492
132	Exelixis Clinical Site #117	Ramat Gan		Israel	5265601
133	Exelixis Clinical Site #30	Safed		Israel	1311001
134	Exelixis Clinical Site #35	Tel Aviv		Israel	6423906
135	Exelixis Site #168	Meldola	FC	Italy	47014
136	Exelixis Site #156	Sondrio	SO	Italy	23100
137	Exelixis Clinical Site #199	Trento	Trentino	Italy	38122
138	Exelixis Clinical Site #217	Ancona		Italy	60126
139	Exelixis Clinical Site #121	Firenze		Italy	50134
140	Exelixis Clinical Site #192	Milan		Italy	20132
141	Exelixis Clinical Site #107	Perugia		Italy	06132
142	Exelixis Clinical Site #62	Roma		Italy	00144
143	Exelixis Clinical Site #234	Roma		Italy	00168
144	Exelixis Clinical Site #96	Terni		Italy	05100
145	Exelixis Clinical Site #233	Toyohashi	Aichi	Japan	471-8513
146	Exelixis Clinical Site #100	Akita-Shi	Akita	Japan	010-8543
147	Exelixis Clinical Site #104	Hirosaki	Aomori	Japan	036-8563
148	Exelixis Clinical Site #43	Kashiwa-shi	Chiba	Japan	277-8577
149	Exelixis Clinical Site #54	Sakura-shi	Chiba	Japan	285-8741
150	Exelixis Clinical Site #72	Sapporo	Hokkaido	Japan	060-8543
151	Exelixis Clinical Site #37	Sapporo	Hokkaido	Japan	060-8648
152	Exelixis Clinical Site #70	Kobe	Hyogo	Japan	650-0017
153	Exelixis Clinical Site #52	Kobe	Hyogo	Japan	650-0047
154	Exelixis Clinical Site #84	Kita-gun	Kagawa	Japan	761-0793
155	Exelixis Clinical Site #68	Sagamihara	Kanagawa	Japan	252-0375
156	Exelixis Clinical Site #22	Yokohama-shi	Kanagawa	Japan	232-0024
157	Exelixis Clinical Site #211	Natori-shi	Miyagi	Japan	981-1293
158	Exelixis Clinical Site #88	Chuo-Ku	Osaka-shi	Japan	541-8567
159	Exelixis Clinical Site #51	Hidaka	Saitama	Japan	350-1298
160	Exelixis Clinical Site #214	Shizuoka City	Shizuoka	Japan	420-8527
161	Exelixis Clinical Site #65	Shinjuku-Ku	Tokyo	Japan	160-8582
162	Exelixis Clinical Site #61	Ube	Yamaguchi	Japan	755-8505
163	Exelixis Clinical Site #78	Chiba		Japan	260-8717
164	Exelixis Clinical Site #209	Fukuoka		Japan	815-8588
165	Exelixis Clinical Site #26	Nagano		Japan	381-8551
166	Exelixis Clinical Site #75	Tokyo		Japan	135-8550
167	Exelixis Clinical Site #32	Wakayama		Japan	641-8510
168	Exelixis Clinical Site #81	Ōsaka-sayama		Japan	589-8511
169	Exelixis Clinical Site #20	Junggu	Daejeon	Korea, Republic of	35015
170	Exelixis Clinical Site #49	Goyang-si	Gyeonggi-do	Korea, Republic of	10408
171	Exelixis Clinical Site #60	Seongnam-si	Gyeonggi-Do	Korea, Republic of	13620
172	Exelixis Clinical Site #34	Hwasun	Jeollanam-do	Korea, Republic of	58128
173	Exelixis Clinical Site #58	Busan		Korea, Republic of	47392
174	Exelixis Clinical Site #24	Busan		Korea, Republic of	49241
175	Exelixis Clinical Site #94	Daegu		Korea, Republic of	41404
176	Exelixis Clinical Site #21	Daegu		Korea, Republic of	42601
177	Exelixis Clinical Site #40	Gwangju		Korea, Republic of	61469
178	Exelixis Clinical Site #59	Seoul		Korea, Republic of	03080
179	Exelixis Clinical Site #46	Seoul		Korea, Republic of	03722
180	Exelixis Clinical Site #25	Seoul		Korea, Republic of	06273
181	Exelixis Clinical Site #48	Seoul		Korea, Republic of	06351
182	Exelixis Clinical Site #206	Tuxtla Gutiérrez	Chiapas	Mexico	29038
183	Exelixis Clinical Site #187	Mexico City	Distrito Federal	Mexico	06760
184	Exelixis Clinical Site #215	Guadalajara	Jalisco	Mexico	44500
185	Exelixis Clinical Site #173	Guadalajara	Jalisco	Mexico	44600
186	Exelixis Clinical Site #219	Zapopan	Jalisco	Mexico	45040
187	Exelixis Clinical Site #172	Querétaro	Queretaro	Mexico	76070
188	Exelixis Clinical Site #182	Querétaro	Queretaro	Mexico	76230
189	Exelixis Clinical Site #184	San Luis Potosí	San Luis Potosi	Mexico	78209
190	Exelixis Clinical Site #208	Culiacán	Sinaloa	Mexico	C.P. 80020
191	Exelixis Clinical Site #174	Mexico City		Mexico	01120
192	Exelixis Clinical Site #82	Bydgoszcz		Poland	85-796
193	Exelixis Clinical Site #89	Poznań		Poland	60-569
194	Exelixis Clinical Site #110	Braga		Portugal	4710-243
195	Exelixis Clinical Site #188	Guimarães		Portugal	4835-044
196	Exelixis Site #164	Lisboa		Portugal	1400-038
197	Exelixis Clinical Site #197	Lisboa		Portugal	1500-650
198	Exelixis Clinical Site #196	Loures		Portugal	2674-514
199	Exelixis Clinical Site #56	Porto		Portugal	4099-001
200	Exelixis Clinical Site #224	Porto		Portugal	4200-072
201	Exelixis Clinical Site #193	Vila Real		Portugal	5000-508
202	Exelixis Site #166	Moscow		Russian Federation	115478
203	Exelixis Clinical Site #137	Saint Petersburg		Russian Federation	197022
204	Exelixis Clinical Site #195	Saint Petersburg		Russian Federation	197758
205	Exelixis Clinical Site #50	Singapore		Singapore	169610
206	Exelixis Clinical Site #87	Singapore		Singapore	258499
207	Exelixis Clinical Site #181	Singapore		Singapore	329563
208	Exelixis Clinical Site #232	Santiago De Compostela	A Coruna	Spain	15706
209	Exelixis Clinical Site #229	Elche	Alicante	Spain	03203
210	Exelixis Clinical Site #223	Oviedo	Asturias	Spain	33011
211	Exelixis Clinical Site #12	Manresa	Barcelona	Spain	08243
212	Exelixis Clinical Site #220	Palma De Mallorca	Islas Baleares	Spain	07120
213	Exelixis Clinical Site #17	Alcorcón	Madrid	Spain	28922
214	Exelixis Clinical Site #227	Barcelona		Spain	08003
215	Exelixis Clinical Site #23	Barcelona		Spain	08035
216	Exelixis Clinical Site #190	Barcelona		Spain	08041
217	Exelixis Clinical Site #226	Cadiz		Spain	11407
218	Exelixis Clinical Site #33	Córdoba		Spain	14004
219	Exelixis Clinical Site #28	Lugo		Spain	27003
220	Exelixis Clinical Site #131	Madrid		Spain	28033
221	Exelixis Clinical Site #13	Madrid		Spain	28050
222	Exelixis Clinical Site #29	Sevilla		Spain	41009
223	Exelixis Clinical Site #138	Kaohsiung		Taiwan	833
224	Exelixis Clinical Site #86	Taichung City		Taiwan	404
225	Exelixis Clinical Site #133	Taichung		Taiwan	407
226	Exelixis Clinical Site #111	Tainan		Taiwan	704
227	Exelixis Clinical Site #102	Dnipro		Ukraine	49005
228	Exelixis Clinical Site #186	Dnipro		Ukraine	49102
229	Exelixis Clinical Site #76	Kyiv		Ukraine	02125
230	Exelixis Clinical Site #71	Luts'k		Ukraine	43018
231	Exelixis Clinical Site #205	London	England	United Kingdom	SE1 9RT
232	Exelixis Clinical Site #231	Northwood	Middlesex	United Kingdom	HA6 2RN
233	Exelixis Clinical Site #194	Swansea	Wales	United Kingdom	SA2 Q8A